Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Calcitriol | The serum concentration of Magnesium levulinate can be increased when it is combined with Calcitriol. |
| Calcifediol | The serum concentration of Magnesium levulinate can be increased when it is combined with Calcifediol. |
| Ergocalciferol | The serum concentration of Magnesium levulinate can be increased when it is combined with Ergocalciferol. |
| Cholecalciferol | The serum concentration of Magnesium levulinate can be increased when it is combined with Cholecalciferol. |
| Paricalcitol | The serum concentration of Magnesium levulinate can be increased when it is combined with Paricalcitol. |
| Dihydrotachysterol | The serum concentration of Magnesium levulinate can be increased when it is combined with Dihydrotachysterol. |
| Alfacalcidol | The serum concentration of Magnesium levulinate can be increased when it is combined with Alfacalcidol. |
| Seocalcitol | The serum concentration of Magnesium levulinate can be increased when it is combined with Seocalcitol. |
| Inecalcitol | The serum concentration of Magnesium levulinate can be increased when it is combined with Inecalcitol. |
| Becocalcidiol | The serum concentration of Magnesium levulinate can be increased when it is combined with Becocalcidiol. |
| Eldecalcitol | The serum concentration of Magnesium levulinate can be increased when it is combined with Eldecalcitol. |
| 1alpha,24S-Dihydroxyvitamin D2 | The serum concentration of Magnesium levulinate can be increased when it is combined with 1alpha,24S-Dihydroxyvitamin D2. |
| Elocalcitol | The serum concentration of Magnesium levulinate can be increased when it is combined with Elocalcitol. |
| Maxacalcitol | The serum concentration of Magnesium levulinate can be increased when it is combined with Maxacalcitol. |
| Doxercalciferol | The serum concentration of Magnesium levulinate can be increased when it is combined with Doxercalciferol. |
| Vitamin D | The serum concentration of Magnesium levulinate can be increased when it is combined with Vitamin D. |
| 1alpha-Hydroxyvitamin D5 | The serum concentration of Magnesium levulinate can be increased when it is combined with 1alpha-Hydroxyvitamin D5. |
| Previtamin D(3) | The serum concentration of Magnesium levulinate can be increased when it is combined with Previtamin D(3). |
| Deferiprone | Magnesium levulinate can cause a decrease in the absorption of Deferiprone resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Eltrombopag | Magnesium levulinate can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Raltegravir | Magnesium levulinate can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Deferasirox | Magnesium levulinate can cause a decrease in the absorption of Deferasirox resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Halofantrine | Magnesium levulinate can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Misoprostol | The risk or severity of adverse effects can be increased when Magnesium levulinate is combined with Misoprostol. |
| Moxifloxacin | Magnesium levulinate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Grepafloxacin | Magnesium levulinate can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Enoxacin | Magnesium levulinate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Pefloxacin | Magnesium levulinate can cause a decrease in the absorption of Pefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ciprofloxacin | Magnesium levulinate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Trovafloxacin | Magnesium levulinate can cause a decrease in the absorption of Trovafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Nalidixic acid | Magnesium levulinate can cause a decrease in the absorption of Nalidixic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Rosoxacin | Magnesium levulinate can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cinoxacin | Magnesium levulinate can cause a decrease in the absorption of Cinoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Lomefloxacin | Magnesium levulinate can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Gatifloxacin | Magnesium levulinate can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Norfloxacin | Magnesium levulinate can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Levofloxacin | Magnesium levulinate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ofloxacin | Magnesium levulinate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Sparfloxacin | Magnesium levulinate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Temafloxacin | Magnesium levulinate can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Fleroxacin | Magnesium levulinate can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Technetium Tc-99m ciprofloxacin | Magnesium levulinate can cause a decrease in the absorption of Technetium Tc-99m ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Garenoxacin | Magnesium levulinate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Nemonoxacin | Magnesium levulinate can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Flumequine | Magnesium levulinate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Enrofloxacin | Magnesium levulinate can cause a decrease in the absorption of Enrofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Orbifloxacin | Magnesium levulinate can cause a decrease in the absorption of Orbifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Sarafloxacin | Magnesium levulinate can cause a decrease in the absorption of Sarafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Difloxacin | Magnesium levulinate can cause a decrease in the absorption of Difloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Pazufloxacin | Magnesium levulinate can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Prulifloxacin | Magnesium levulinate can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Delafloxacin | Magnesium levulinate can cause a decrease in the absorption of Delafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Sitafloxacin | Magnesium levulinate can cause a decrease in the absorption of Sitafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Oxolinic acid | Magnesium levulinate can cause a decrease in the absorption of Oxolinic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Rufloxacin | Magnesium levulinate can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Pipemidic acid | Magnesium levulinate can cause a decrease in the absorption of Pipemidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Lymecycline | Magnesium levulinate can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Clomocycline | Magnesium levulinate can cause a decrease in the absorption of Clomocycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Oxytetracycline | Magnesium levulinate can cause a decrease in the absorption of Oxytetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Demeclocycline | Magnesium levulinate can cause a decrease in the absorption of Demeclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Tetracycline | Magnesium levulinate can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Metacycline | Magnesium levulinate can cause a decrease in the absorption of Metacycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Minocycline | Magnesium levulinate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Sarecycline | Magnesium levulinate can cause a decrease in the absorption of Sarecycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Omadacycline | Magnesium levulinate can cause a decrease in the absorption of Omadacycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Penimepicycline | Magnesium levulinate can cause a decrease in the absorption of Penimepicycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Isradipine | The risk or severity of hypotension can be increased when Magnesium levulinate is combined with Isradipine. |
| Diltiazem | The risk or severity of hypotension can be increased when Magnesium levulinate is combined with Diltiazem. |
| Trimethadione | The risk or severity of hypotension can be increased when Magnesium levulinate is combined with Trimethadione. |
| Amlodipine | The risk or severity of hypotension can be increased when Magnesium levulinate is combined with Amlodipine. |
| Nimodipine | The risk or severity of hypotension can be increased when Magnesium levulinate is combined with Nimodipine. |
| Nisoldipine | The risk or severity of hypotension can be increased when Magnesium levulinate is combined with Nisoldipine. |
| Lercanidipine | The risk or severity of hypotension can be increased when Magnesium levulinate is combined with Lercanidipine. |
| Cinnarizine | The risk or severity of hypotension can be increased when Magnesium levulinate is combined with Cinnarizine. |
| Ethosuximide | The risk or severity of hypotension can be increased when Magnesium levulinate is combined with Ethosuximide. |
| Nicardipine | The risk or severity of hypotension can be increased when Magnesium levulinate is combined with Nicardipine. |
| Magnesium sulfate | The risk or severity of hypotension can be increased when Magnesium levulinate is combined with Magnesium sulfate. |
| Verapamil | The risk or severity of hypotension can be increased when Magnesium levulinate is combined with Verapamil. |
| Zonisamide | The risk or severity of hypotension can be increased when Magnesium levulinate is combined with Zonisamide. |
| Felodipine | The risk or severity of hypotension can be increased when Magnesium levulinate is combined with Felodipine. |
| Nitrendipine | The risk or severity of hypotension can be increased when Magnesium levulinate is combined with Nitrendipine. |
| Perhexiline | The risk or severity of hypotension can be increased when Magnesium levulinate is combined with Perhexiline. |
| Nifedipine | The risk or severity of hypotension can be increased when Magnesium levulinate is combined with Nifedipine. |
| Amiodarone | The risk or severity of hypotension can be increased when Magnesium levulinate is combined with Amiodarone. |
| Carvedilol | The risk or severity of hypotension can be increased when Magnesium levulinate is combined with Carvedilol. |
| Bepridil | The risk or severity of hypotension can be increased when Magnesium levulinate is combined with Bepridil. |
| Mibefradil | The risk or severity of hypotension can be increased when Magnesium levulinate is combined with Mibefradil. |
| Nimesulide | The risk or severity of hypotension can be increased when Magnesium levulinate is combined with Nimesulide. |
| Prenylamine | The risk or severity of hypotension can be increased when Magnesium levulinate is combined with Prenylamine. |
| Cyclandelate | The risk or severity of hypotension can be increased when Magnesium levulinate is combined with Cyclandelate. |
| Flunarizine | The risk or severity of hypotension can be increased when Magnesium levulinate is combined with Flunarizine. |
| Fluspirilene | The risk or severity of hypotension can be increased when Magnesium levulinate is combined with Fluspirilene. |
| Clevidipine | The risk or severity of hypotension can be increased when Magnesium levulinate is combined with Clevidipine. |
| Methsuximide | The risk or severity of hypotension can be increased when Magnesium levulinate is combined with Methsuximide. |
| Seletracetam | The risk or severity of hypotension can be increased when Magnesium levulinate is combined with Seletracetam. |
| Nylidrin | The risk or severity of hypotension can be increased when Magnesium levulinate is combined with Nylidrin. |
| Ziconotide | The risk or severity of hypotension can be increased when Magnesium levulinate is combined with Ziconotide. |
| Dotarizine | The risk or severity of hypotension can be increased when Magnesium levulinate is combined with Dotarizine. |
| Nilvadipine | The risk or severity of hypotension can be increased when Magnesium levulinate is combined with Nilvadipine. |
| Tranilast | The risk or severity of hypotension can be increased when Magnesium levulinate is combined with Tranilast. |